Factors influencing adherence to cancer treatment in older adults with cancer: A systematic review

Annals of Oncology

Volumn 25, Issue 3, 2014, Pages 564-577

  Puts, M T E ^a   Tu, H A ^a,b   Tourangeau, A ^a   Howell, D ^a,c   Fitch, M ^a,d   Springall, E ^a   Alibhai, S M H ^e,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aged; Cancer treatment; Geriatric oncology; Non adherence; Systematic review

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

ADULT; BREAST CANCER; CANCER HORMONE THERAPY; COCHRANE LIBRARY; COGNITION; COMORBIDITY; CROSS-SECTIONAL STUDY; HUMAN; LONGITUDINAL STUDY; MOLECULARLY TARGETED THERAPY; MORBIDITY; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITATIVE RESEARCH; QUALITY CONTROL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

AGED; CANCER TREATMENT; GERIATRIC ONCOLOGY; NON-ADHERENCE; SYSTEMATIC REVIEW;

AGED; AGED, 80 AND OVER; AGING; COST-BENEFIT ANALYSIS; HUMANS; MEDICATION ADHERENCE; NEOPLASMS;

EID: 84896807336     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt433     Document Type: Review

References (74)

1. Canadian Cancer Society's Steering Committee on Cancer statistics. Canadian Cancer Statistics 2013. Canadian Cancer Society. Toronto, Canada: Canadian Cancer Society 2013.
2. Smith BD, Smith GL, Hurria A et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009; 27: 2758-2765.
3. Sabata E; on behalf of the WHO. Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization 2003.
4. Ganesan P, Sagar TG, Dubashi B et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011; 86(6): 471-474.
5. Mazzeo F, Duck L, Joosens E et al. Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study. Anticancer Res 2011; 31 (4): 1407-1409.
6. Hershman DL, Shao T, Kushi LH et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 2011; 126(2): 529-537.
7. McCowan C, Shearer J, Donnan PT et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008; 99(11): 1763-1768.
8. Srokowski TP, Fang S, Duan Z et al. Completion of adjuvant radiation therapy among women with breast cancer. Cancer 2008; 113: 22-29.
9. Ibrahim AR, Eliasson L, Apperley JF et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on longterm therapy. Blood 2011; 117(14): 3733-3736.
10. Allemani C, Storm H, Voogd AC et al. Variation in 'standard care' for breast cancer across Europe: A EUROCARE-3 high resolution study. Eur J Cancer 2010; 46: 1528-1536.
11. Darkow T, Henk HJ, Thomas SK et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007; 25: 481-496.
12. Marin D, Bazeos A, Mahon FX et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381-2388.
13. The Chief Public Health Officer. The Chief Public Health Officer's annual report on the state of Public Health in Canada 2010: growing older-adding life to years. The Chief Public Health officer. Ottawa, Canada: Public Health Canada 2010.
14. Canadian Institute for Health Information. Drug use among seniors on public drug programs in Canada 2002 to 2008. Ottawa, ON: CIHI. 1-7-2012 2010.
15. Mangin D, Heath I, Jamoulle M. Beyond diagnosis: rising to the multimorbidity challenge. BMJ 2012; 344: e3526.
16. Salisbury C. Multimorbidity: redesigning health care for people who use it. Lancet 2012; 380: 7-9.
17. Ritchie CS, Kvale E, Fisch MJ. Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract 2011; 7: 371-374.
18. Banning M. Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review. Eur J Cancer Care 2012; 21(1): 10-19.
19. Banning M. Older people and adherence with medication: a review of the literature. Int J Nurs Stud 2008; 45: 1550-1561.
20. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging 2004; 21: 793-811.
21. Schuz B, Marx C, Wurm S et al. Medication beliefs predict medication adherence in older adults with multiple illnesses. J Psychosom Res 2011; 70: 179-187.
22. Pound P, Britten N, Morgan M et al. Resisting medicines: a synthesis of qualitative studies of medicine taking. Soc Sci Med 2005; 61: 133-155.
23. Mishra SI, Gioia D, Childress S et al. Adherence to medication regimens among low-income patients with multiple comorbid chronic conditions. Health Soc Work 2011; 36: 249-258.
24. Schlenk EA, Dunbar-Jacob J, Engberg S. Medication non-adherence among older adults: a review of strategies and interventions for improvement. J Gerontol Nurs 2004; 30: 33-43.
25. Verbrugghe M, Verhaeghe S, Lauwaert K et al. Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review. Cancer Treat Rev 2013; 39: 610-621.
26. Given BA, Spoelstra SL, Grant M. The challenges of oral agents as antineoplastic treatments. Semin Oncol Nurs 2011; 27: 93-103.
27. Spoelstra SL, Given CW. Assessment and measurement of adherence to oral antineoplastic agents. Semin Oncol Nurs 2011; 27: 116-132.
28. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009; 59: 56-66.
29. Foulon V, Schoffski P, Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg 2011; 66: 85-96.
30. Barton D. Oral agents in cancer treatment: the context for adherence. Semin Oncol Nurs 2011; 27: 104-115.
31. Palmieri FM, Barton DL. Challenges of oral medications in patients with advanced breast cancer. Semin Oncol Nurs 2007; 23: S17-S22.
32. Hohneker J, Shah-Mehta S, Brandt PS. Perspectives on adherence and persistence with oral medications for cancer treatment. J Oncol Pract 2011; 7: 65-67.
33. Moher D, Liberati A, TetzlaffJ et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-341.
34. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-47.
35. Pace R, Pluye P, Bartlett G et al. Testing the reliability and efficiency of the pilot Mixed Methods Appraisal Tool (MMAT) for systematic mixed studies review. Int J Nurs Stud 2012; 49: 47-53.
36. Barcenas CH, Zhang N, Zhao H et al. Anthracycline regimen adherence in older patients with early breast cancer. Oncologist 2012; 17: 303-311.
37. Barron TI, Connolly RM, Bennett K et al. Early discontinuation of tamoxifen-A lesson for oncologists. Cancer 2007; 109: 832-839.
38. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001; 19: 322-328.
39. Dobie SA, Baldwin LM, Dominitz JA et al. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 2006; 98(9): 610-619.
40. Fesinmeyer MD, Mehta V, Tock L et al. Completion of radiotherapy for local and regional head and neck cancer in medicare. Arch Otolaryngol Head Neck Surg 2009; 135: 860-867.
41. Fink AK, Gurwitz J, Rakowski W et al. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 2004; 22(16): 3309-3315.
42. Guth U, Huang DJ, Schotzau A et al. Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 2008; 99(3): 428-433.
43. Guth U, Myrick ME, Schotzau A et al. Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: How often and how often does it work? Breast Cancer Res Treat 2011; 129(3): 799-807.
44. Guth U, Myrick ME, Kandler C et al. The use of adjuvant endocrine breast cancer therapy in the oldest old. Breast 2013; 22(5): 863-868.
45. Hoskin PJ, Rojas AM, Saunders MI et al. Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial. Radiother Oncol 2009; 91(1): 120-125.
46. Kimmick G, Anderson R, Camacho F et al. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 2009; 27(21): 3445-3451.
47. Lash TL, Fox MP, Westrup JL et al. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006;99(2): 215-220.
48. Lau FW, Choi KT, Wei WI et al. Induction chemotherapy for oral cancers in a noncompliant patient population. Asian J Surg 1994; 17(3): 277-282.
49. Neugut AI, Subar M, Wilde ET et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with earlystage breast cancer. J Clin Oncol 2011; 29(18): 2534-2542.
50. Owusu C, Buist DS, Field TS et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008; 26 (4): 549-555.
51. Partridge AH, Archer L, Kornblith AB et al. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010; 28(14): 2418-2422.
52. Partridge AH, Wang PS, Winer EP et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003; 21(4): 602-606.
53. Regnier DV, Poirson J, Nourissat A et al. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists. Eur J Cancer Care 2011; 20(4): 520-527.
54. Ruddy KJ, Pitcher BN, Archer LE et al. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol 2012; 23(12): 3075-3081.
55. Shaheen JA, Amin M, Harty JI. Patient compliance in treatment of prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonist. Urology 1993; 42(5): 533-535.
56. Winterhalder R, Hoesli P, Delmore G et al. Self-reported compliance with capecitabine: findings from a prospective cohort analysis. Oncology 2011; 80(1-2): 29-33.
57. Ziller V, Kalder M, Albert U-S et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009; 20(3): 431-436.
58. Townsley C, Pond GR, Peloza B et al. Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol 2005; 23: 3802-3810.
59. Persons in low-income after tax 2006-2010. Ottawa, Canada: Statistics Canada. 2013.
60. Longo CJ, Deber R, Fitch M et al. An examination of cancer patients' monthly 'out-of-pocket' costs in Ontario, Canada. Eur J Cancer Care (Engl) 2007; 16: 500-507.
61. Longo CJ, Fitch M, Deber RB et al. Financial and family burden associated with cancer treatment in Ontario, Canada. Support Care Cancer 2006; 14: 1077-1085.
62. Retornaz F, Monette J, Batist G et al. Usefulness of frailty markers in the assessment of the health and functional status of older cancer patients referred for chemotherapy: a pilot study. J Gerontol A Biol Sci Med Sci 2008; 63: 518-522.
63. Puts MT, Monette J, Girre V et al. Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study. Crit Rev Oncol Hematol 2011; 78: 138-149.
64. Amalraj S, Starkweather C, Nguyen C et al. Health literacy, communication, and treatment decision-making in older cancer patients. Oncology (Williston Park) 2009; 23: 369-375.
65. McCarthy DM, Waite KR, Curtis LM et al. What did the doctor say? Health literacy and recall of medical instructions. Med Care 2012; 50: 277-282.
66. Zamora H, Clingerman EM. Health literacy among older adults: a systematic literature review. J Gerontol Nurs 2011; 37: 41-51.
67. Ngoh LN. Health literacy: a barrier to pharmacist-patient communication and medication adherence. J Am Pharm Assoc 2009; 49: e132-e146.
68. Papamichael D, Audisio R, Horiot JC et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 2009; 20: 5-16.
69. Biganzoli L, Wildiers H, Oakman C et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012; 13(4): e148-e160.
70. Aapro M, Bernard-Marty C, Brain EG et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol 2011; 22: 257-267.
71. Droz J-P, Balducci L, Bolla M et al. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Critical Rev Oncol/Hematol 2010; 73(1): 68-91.
72. Hurria A, Browner IS, Cohen HJ et al. Senior adult oncology: Clinical practice guidelines in oncology. JNCCN 2012; 10(2): 162-209.
73. Balducci L. Pharmacology of antineoplastic medications in older cancer patients. Oncology (Williston Park) 2009; 23: 78-85.
74. Extermann M. Geriatric oncology: an overview of progresses and challenges. Cancer Res Treat 2010; 42: 61-68.